Immunotherapy of MHC class I-deficient tumors

Future Oncology

Volumn 6, Issue 10, 2010, Pages 1577-1589

  Reini, Milan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

antigen presenting machinery; antitumor immunotherapy; epigenetics; MHC class I expression; tumor vaccine

Indexed keywords

CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; EPIGENETICS; INNATE IMMUNITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 78149422805     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.128     Document Type: Review

References (97)

1. Dougan M, Dranoff G: Immune therapy for cancer. Annu. Rev. Immunol. 27, 83-117 (2009).
2. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2), 137-148 (2004).
3. Zou W: Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005).
4. Garrido F, Cabrera T, Lopez-Nevot MA et al.: HLA class I antigens in human tumors. Adv. Cancer Res. 67, 155-195 (1995).
5. Aptsiauri N, Carretero R, Garcia-Lora A et al.: Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol. Immunother. 57(11), 1727-1733 (2008).
6. Hicklin DJ, Marincola FM, Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5(4), 178-186 (1999).
7. Garrido F, Ruiz-Cabello F, Cabrera T et al.: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18(2), 89-95 (1997).
8. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Immunology 3(11), 999-1005 (2002).
9. Bijen CB, Bantema-Joppe EJ, de Jong RA et al.: The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int. J. Cancer 126(6), 1417-1427 (2010).
10. Seliger B, Ritz U, Ferrone S: Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int. J. Cancer 118(1), 129-138 (2006).
11. Bubeník J: Prospects for immunotherapy of MHC class I-defcient tumours. Folia Biol. (Praha) 49(3), 95-99 (2003). (Pubitemid 36818238)
12. Ploegh HL: Viral strategies of immune evasion. Science 280(5361), 248-253 (1998).
13. Blagoveshchenskaya AD, Thomas L, Feliciangeli SF et al.: HIV-1 Nef downregulates MHC-I by a PACS-1-and PI3K-regulated ARF6 endocytic pathway. Cell 111(6), 853-866 (2002).
14. Suárez-Alvarez B, Rodriguez RM, Calvanese V et al.: Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS ONE 5(14), E10192 (2010).
15. + cytotoxic T lymphocyte that mediate specifc tumor rejection. J. Immunol. 151(11), 6283-6290 (1993).
16. Menon AG, Janssen-van Rhijn CM, Morreau H et al.: Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab. Invest. 84(4), 493-501 (2004).
17. Bubenik J: Tumor MHC class I downregulation and immunotherapy (review). Oncol. Rep. 10(6), 2005-2008 (2003).
18. Chang CC, Campoli M, Ferrone S: HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr. Opin. Immunol. 16(5), 644-650 (2004).
19. Blanchet O, Bourge JF, Zinszner H et al.: Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc. Natl Acad. Sci. USA 89(8), 3488-3492 (1992).
20. 2 microglobulin by interferon-γ. EMBO J. 8(2), 475-481 (1989).
21. Sibille C, Gould K, Hämmerling G et al.: A defect in the presentation of intracellular viral antigens is restored by interferon-γ in cell lines with impaired major histocompatibility complex class I assembly Eur. J. Immunol. 22(2), 433-440 (1992).
22. 2 microglobulin and antigenic peptides. J. Immunol. 151(6), 2974-2985 (1993).
23. Gabathuler R, Reid G, Kolaitis G et al.: Comparison of cell lines defcient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J. Exp. Med. 180(4), 1415-1425 (1994).
24. Setiadi AF, David MD, Chen SS et al.: Identifcation of mechanisms underlying transporter associated with antigen processing defciency in metastatic murine carcinomas. Cancer Res. 65(16), 7485-92 (2005).
25. Seliger B, Schreiber K, Delp K et al.: Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 57(1), 39-45 (2001).
26. Garcia-Lora A, Martinez M, Algarra I et al.: MHC class I-defcient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int. J. Cancer 106(4), 521-527 (2003).
27. Seliger B, Wollscheid U, Momburg F et al.: Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56(4), 327-336 (2000).
28. Pantel K, Schlimok G, Kutter D et al.: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51(17), 4712-4715 (1991).
29. Cabrera T, Pedrajas G, Cozar JM et al.: HLA class I expression in bladder carcinomas. Tissue Antigens 62(4), 324-327 (2003).
30. Vertuani S, De Geer A, Levitsky V et al.: Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res. 63(22), 8006-8013 (2003).
31. Campoli M, Ferrone S: HLA antigen changes in malignant cells: epigenetic mechanisms and biologic signifcance. Oncogene 27(45), 5869-5885 (2008).
32. Serrano A, Tanzarella S, Lionello I et al.: Rexpression of HLA class I antigens and restoration of antigen-specifc CTL response in melanoma cells following 5-aza-2́-deoxycytidine treatment. Int. J. Cancer 94(2), 243-251 (2001). (Pubitemid 32911420)
33. Nie Y, Yang G, Song Y et al.: DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22(10), 1615-1623 (2001).
34. Setiadi AF, David MD, Seipp RP et al.: Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol. Cell Biol. 27(22), 7886-7894 (2007).
35. Manning J, Indrova M, Lubyova B et al.: Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123 (2), 218-227 (2008).
36. Setiadi AF, Omilusik K, David MD et al.: Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 68(23), 9601-9607 (2008).
37. Khan AN, Gregorie CJ, Tomasi TB: Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 57(5), 647-654 (2008).
38. Khan AN, Tomasi TB: Histone deacetylase regulation of immune gene expression in tumor cells. Immunol. Res. 40(2), 164-178 (2008).
39. Tomasi TB, Magner WJ, Khan AN: Epigenetic regulation of immune escape genes in cancer. Cancer Immunol. Immunother. 55(10), 1159-1184 (2006).
40. Karre K, Ljunggren HG, Piontek G et al.: Selective rejection of H-2-defcient lymphoma variants suggests alternative immune defence strategy. Nature 319(6055), 675-678 (1986).
41. Diefenbach A, Raulet DH: The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 188(1), 9-21 (2002).
42. Kim KD, Choi SC, Kim A et al.: Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction. Int. Immunopharmacol. 1(12), 2117-2129 (2001).
43. + HPV16-associated tumours. Folia Biol. (Praha) 50(6), 200-202 (2004).
44. Watson NF, Ramage JM, Madjd Z et al.: Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J.Cancer 118(1), 6-10 (2006).
45. Leffers N, Lambeck AJ, de Graeff P et al.: Survival of ovarian cancer patients overexpressing the tumor antigen p53 is diminished in case of MHC class I down-regulation. Gynecol. Oncol. 110(3), 365-373 (2008).
46. Madjd Z, Spendlove I, Pinder SE et al.: Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int. J. Cancer 117(2), 248-255 (2005).
47. Sandel MH, Speetjens FM, Menon AG et al.: Natural killer cells infltrating colorectal cancer and MHC class I expression. Mol. Immunol. 42(4), 541-546 (2005).
48. Indrová M, Bieblová J, Rossowska J et al.: HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumor infltrating cells after chemotherapy Int. J. Oncol. 34(1), 173-179 (2009).
49. Le Maux Chansac B, Moretta A, Vergnon I et al.: NK cells infltrating a MHC class I-defcient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J. Immunol. 175(9), 5790-5798 (2005).
50. Moretta L, Bottino C, Pende D et al.: Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol. Lett. 100(1), 7-13 (2005).
51. Groh V, Wu J, Yee C et al.: Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908), 734-738 (2002).
52. Doubrovina ES, Doubrovin MM, Vider E et al.: Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171(12), 6891-6899 (2003).
53. Sers C, Kuner R, Falk CS et al.: Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int. J. Cancer 125(7), 1626-1639 (2009).
54. Rohner A, Langenkamp U, Siegler U et al.: Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk. Res. 31(10), 1393-1402 (2007).
55. Skov S, Pedersen MT, Andresen L et al.: Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65(23), 11136-11145 (2005).
56. Bubenik J, Vonka V: MHC class I status of tumours and design of immunotherapeutic strategies. Immunol. Lett. 90(2-3), 177-178 (2003).
57. Bubenik J: MHC class I down-regulation: tumor escape from immune surveillance? (review). Int. J. Oncol. 25(2), 487-491 (2004).
58. Mocikat R, Braumüller H, Gumy A et al.: Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19(4), 561-569 (2003).
59. -tumours of HPV16 origin. Int. J Oncol. 20(3), 643-646 (2002).
60. Bubenik J, Mikyskova R, Vonka V et al.: Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21(9-10), 891-896 (2003).
61. Bubenik J: Animal models for development of therapeutic HPV16 vaccines (review). Int. J. Oncol. 20(1), 207-212 (2002).
62. Reinis M, Simova J, Bubenik J: Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-defcient and-profcient HPV16-associated tumours. Int. J. Cancer 118(7), 1836-1842 (2006).
63. Símová J, Indrová M, Bieblová J et al.: Therapy for minimal residual tumor disease: β-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy Int. J. Cancer 126(12), 2997-3004 (2010).
64. Grant JF, Iwasawa T, Sinn HW et al.: Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-α combination therapy Int. J. Cancer 119(11), 2632-2641 (2006).
65. Nanni P, Rossi I, De Giovanni C et al.: Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 58(6), 1225-1230 (1998).
66. Levitsky HI, Lazenby A, Hayashi RJ et al.: In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179(4), 1215-1224 (1994).
67. Lasek W, Mackiewicz A, Czajka A et al.: Antitumor effects of the combination therapy with TNF-α gene-modifed tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther. 7(12), 1581-1590 (2000).
68. + T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther. 10(16), 1311-1320 (2003).
69. Cheng WF, Hung CF, Lee CN et al.: Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. Eur. J. Immunol. 34(7), 1892-1900 (2004).
70. Nemeckova S, Smahel M, Hainz P et al.: Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules. Neoplasma 54(4), 326-333 (2007).
71. + T-cell cytotoxicity. Cancer Res. 69(16), 6615-6623 (2009).
72. Douin-Echinard V, Bornes S, Rochaix P et al.: The expression of CD70 and CD80 by gene-modifed tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther. 7(12), 1543-1556 (2000).
73. Nausch N, Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27(45), 5944-5958 (2008).
74. Vahlne G, Lindholm K, Meier A et al.: In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2. Eur. J. Immunol. 40(3), 813-823 (2010).
75. Niederhafner P, Reinis M, Sebestík J et al.: Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases. J. Pept. Sci. 14(5), 556-587 (2008).
76. Reinis M, Stepanek I, Simova J et al.: Induction of protective immunity against MHC class I-defcient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int. J. Oncol. 36(3), 545-551 (2010).
77. + and class I-HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments. Folia Biol. (Praha) 49(6), 230-234 (2003).
78. Reinis M, Símová J, Indrová M et al.: Immunisation with MHC class I-negative but not-positive HPV16-associated tumor cells inhibits growth of MHC class I-negative tumours. Int. J. Oncol. 30(4), 1011-1017 (2007).
79. Keating PJ, Cromme FV, Duggan-Keen M et al.: Frequency of down-regulation of individual HLA-A and-B alleles in cervical carcinomas in relation to TAP-1 expression. Br. J. Cancer 72(2), 405-411 (1995).
80. van Hall T, Wolpert EZ, van Veelen P et al.: Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 12(4), 417-424 (2006).
81. + T cells specifc for hydrophobic TAP-and tapasin-independent peptides: the requirement for directed access into the ER. Cancer Immunol. Immunother. 56(8), 1143-1152 (2007).
82. Chambers B, Grufman P, Fredriksson V et al.: Induction of protective CTL immunity against peptide transporter TAP-defcient tumors through dendritic cell vaccination. Cancer Res. 67(18), 8450-8455 (2007).
83. + T cell surveillance of antigen-processing defects. J. Exp. Med. 207(1), 207-221 (2010).
84. Propper DJ, Chao D, Braybrooke JP et al.: Low-dose IFN-γ induces tumor MHC expression in metastatic malignant melanoma. Clin. Cancer Res. 9(1), 84-92 (2003).
85. Martini M, Testi MG, Pasetto M et al.: IFN-γ-mediated upmodulation of MHC class I expression activates tumor-specifc immune response in a mouse model of prostate cancer. Vaccine 28(20), 3548-3557 (2010).
86. Schwinn N, Vokhminova D, Sucker A et al.: Interferon-γ down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-defcient melanoma by natural killer cells. Int. J. Cancer 124(7), 1594-1604 (2009).
87. Mikyskova R, Bubenik J, Vonka V et al.: Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy Int. J. Oncol. 26(2), 521-527 (2005).
88. Kijima M, Saio M, Oyang GF et al.: Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int. J. Oncol. 26(3), 679-684 (2005).
89. Ouyang GF, Saio M, Suwa T et al.: Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int. J. Oncol. 28(5), 1201-1208 (2006).
90. Reits EA, Hodge JW, Herberts CA et al.: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J. Exp. Med. 203(5), 1259-1271 (2006).
91. Alimonti J, Zhang QJ, Gabathuler R et al.: TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat. Biotechnol. 18(5), 515-520 (2000).
92. Lou Y, Seipp RP, Cai B et al.: Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. Vaccine 25(12), 2331-2339 (2007).
93. Lou Y, Vitalis TZ, Basha G et al.: Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specifc immune responses and survival. Cancer Res. 65(17), 7926-7933 (2005).
94. Lou Y, Basha G, Seipp RP et al.: Combining the antigen processing components TAP and tapasin elicits enhanced tumor-free survival. Clin. Cancer Res. 14(5), 1494-1501 (2008).
95. Smahel M, Sobotková E, Bubeník J et al.: Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84(3), 374-380 (2001).
96. Jinoch P, Zak R, Janousková O et al.: Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2. Int. J. Oncol. 223(3), 775-783 (2003).
97. Smahel M, Pokorná D, Macková J et al.: Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli β-glucuronidase. J. Gene Med. 6(10), 1092-1101 (2004).